IKT-001 not checked

Inhibikase Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
2 active
2 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
Main trialPhase 3
“This is an adaptive, 2-part, randomized, multicenter, double-blind, placebo-controlled, parallel-group study designed to evaluate the efficacy and safety of IKT-001 in adult participants with WHO Group 1 PAH.”In the company’s words, NCT07365332 on ClinicalTrials.gov

Other drugs for Pulmonary Arterial Hypertension

All 24 drugs for Pulmonary Arterial Hypertension

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Jun 2029 An Adaptive Program of IKT-001 in Pulmonary Arterial Hypertension (PAH)
Phase 3Not yet recruiting 30 Jun 2030 Open-Label Study of IKT-001 in Pulmonary Arterial Hypertension (PAH)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow IKT-001

Following is part of Solo: you see every change to IKT-001 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in